Industry and clinical experts will discuss the future of gene therapies in addressing vision diseases, including the major milestones achieved to date and the significant advances on the horizon.
-
Alexander Anetakis, MD, MBA, Vitreo-retinal Surgeon, UPMC, and Physician-Advisor, UPMC Enterprises (Moderator)
-
Dan Chung, MD, Chief Medical Officer, SparingVision
-
Rob Lin, PhD, CFA, Chief Executive Officer, Avista Therapeutics
Key topics for discussion:
-
Long-term efficacy of gene therapies and degeneration over time.
-
Challenges with manufacturing gene therapies.
-
Addressing the high costs and accessibility of gene therapies.
-
Optimizing delivery methods for gene therapies.
-
Potential for combinations of gene therapy and other treatments, such as drugs or stem cell therapies.
-
What is needed to expand targets for gene therapies beyond specific mutations.